{"id":"W2594051854","doi":"10.1016/j.ctarc.2017.02.005","title":"Challenging the Paradigm: EGFR wild-type benefit from an EGFR inhibitor in NSCLC","year":2017,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia Hospital; BC Research (Canada); BC Cancer Agency","funders":"Boehringer Ingelheim; AstraZeneca","keywords":"Afatinib; Erlotinib; Gefitinib; Epidermal growth factor receptor; Lung cancer; Medicine; Erlotinib Hydrochloride; Oncology; EGFR inhibitors; Tyrosine kinase; Internal medicine; Cancer research; Cancer; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0002261976,0.000143176,0.0002126702,0.0001198571,0.002058117,0.0001811593,0.0004970478,0.00007035794,0.0000657687],"category_scores_gemma":[0.00004862108,0.0000894626,0.00004754671,0.0001491607,0.0005041152,0.0002304454,0.0002187362,0.0002869994,0.00001647667],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006419011,"about_ca_system_score_gemma":0.0003807152,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02127941,"about_ca_topic_score_gemma":0.01554828,"domain_scores_codex":[0.9989017,0.0001223511,0.0001763695,0.0002772744,0.0002093258,0.0003129857],"domain_scores_gemma":[0.9969242,0.0002649178,0.00006378553,0.002425374,0.0001454402,0.0001763248],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005209004,0.003235292,0.5022776,0.00004396503,0.001491809,0.00005001411,0.02560386,0.00004698091,0.001106021,0.02390814,0.001254296,0.4404611],"study_design_scores_gemma":[0.006754811,0.001062605,0.8590473,0.000627292,0.000428438,0.000008585856,0.00368531,0.001659748,0.0004676207,0.004979526,0.1210078,0.0002709067],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8528196,0.03947805,0.000002769759,0.09561674,0.0001383298,0.001232943,0.00009085634,0.00003905555,0.01058166],"genre_scores_gemma":[0.9533739,0.04381222,0.000192375,0.00009507071,0.0001750489,0.0006611755,0.0001620616,0.00002106803,0.00150705],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4401902,"threshold_uncertainty_score":0.9992411,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1682299182936018,"score_gpt":0.4979343324553248,"score_spread":0.329704414161723,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}